Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
May 26, 2023 03:42 ET
|
Curium
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
Oncologists Global Market Report 2023: Rising Prevalence of Cancer Fuels the Sector
May 25, 2023 09:53 ET
|
Research and Markets
Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.
May 23, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific co-founder, Dr. Jack A....
Hofseth Biocare ASA: SPIN-OFF OF PROSTATE CANCER CO-TREATMENT PROJECT
May 15, 2023 01:50 ET
|
Hofseth Biocare ASA
Hofseth Biocare ASA ("HBC" or the "Company") today announces the decision to transfer its prostate cancer co-treatment project (the "Project") to a new US entity to be called HBC Immunology Inc....
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
May 08, 2023 16:00 ET
|
FibroGen, Inc.
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential...
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 08, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant...
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 05, 2023 07:00 ET
|
Arvinas Inc.
–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests...
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Cancer Profiling Market Size & Share to Surpass $19.28 Billion by 2030 | Vantage Market Research
April 27, 2023 08:01 ET
|
Vantage Market Research
WASHINGTON, April 27, 2023 (GLOBE NEWSWIRE) -- Global Cancer Profiling Market is valued at USD 9.4 Billion in 2022 and is projected to reach a value of USD 19.28 Billion by 2030 at a CAGR (Compound...
Purdue Research Foundation monetizes Pluvicto royalty interests to fund further research at Purdue University
April 26, 2023 08:00 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind. and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Purdue Research Foundation, a private not-for-profit institute to advance the research of Purdue University, has received more...